IGC Pharma Inc Financials
IGC Pharma Inc (IGC) reported $1.3M in revenue for fiscal year 2025, down 5.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
IGC Pharma’s core operating mechanic is still funding a research-heavy business with outside capital, not with internally generated cash.
From FY2023 to FY2025, operating cash burn improved from-$7.0M to-$4.8M , showing the cost base is coming down. Yet FY2025 financing inflow of$4.5M almost equaled free cash outflow of-$4.9M , so the lower burn changed the pace of funding need more than the funding model itself.
In FY2025, R&D spending was
FY2025 financing inflow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of IGC Pharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
IGC Pharma Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 29/100.
IGC Pharma Inc's revenue declined 5.5% year-over-year, from $1.3M to $1.3M. This contraction results in a growth score of 16/100.
IGC Pharma Inc carries a low D/E ratio of 0.02, meaning only $0.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 87/100, indicating a strong balance sheet with room for future borrowing.
IGC Pharma Inc's current ratio of 1.28 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.
IGC Pharma Inc's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 3/100.
IGC Pharma Inc posts a -112.5% return on equity (ROE), meaning it loses $113 for every $100 of shareholders' equity. This results in a returns score of 32/100. This is up from -177.6% the prior year.
IGC Pharma Inc scores -14.00, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($31.8M) relative to total liabilities ($2.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
IGC Pharma Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
IGC Pharma Inc reported a net loss of $7.1M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
IGC Pharma Inc reported an operating loss of $7.4M against $5K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
IGC Pharma Inc generated $1.3M in revenue in fiscal year 2025. This represents a decrease of 5.5% from the prior year.
IGC Pharma Inc's EBITDA was -$6.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.5% from the prior year.
IGC Pharma Inc reported -$7.1M in net income in fiscal year 2025. This represents an increase of 45.2% from the prior year.
IGC Pharma Inc earned -$0.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 59.1% from the prior year.
Cash & Balance Sheet
IGC Pharma Inc recorded an outflow of $4.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 8.1% from the prior year.
IGC Pharma Inc held $405K in cash against $134K in long-term debt as of fiscal year 2025, with $2.3M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
IGC Pharma Inc's gross margin was 48.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.8 percentage points from the prior year.
IGC Pharma Inc's ROE was -112.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 65.1 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
IGC Pharma Inc invested $3.7M in research and development in fiscal year 2025. This represents a decrease of 3.1% from the prior year.
IGC Pharma Inc invested $112K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 18.8% from the prior year.
Not reported for fiscal year 2025.
IGC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $1.3M-5.5% | $1.3M+47.6% | $911K+129.5% | $397K-55.8% | $898K-77.9% | $4.1M-20.4% | $5.1M+133.3% | $2.2M+277.9% | $580K-90.9% | $6.4M-17.1% | $7.7M+237.9% | $2.3M-71.7% | $8.0M+91.2% | $4.2M+3.1% | $4.1M |
| Cost of Revenue | N/A | $652K+6.5% | $612K+30.5% | $469K+131.0% | $203K-74.1% | $785K-80.2% | $4.0M-20.6% | $5.0M+136.1% | $2.1M+482.9% | $362K-93.4% | $5.5M-22.2% | $7.1M+275.4% | $1.9M-70.9% | $6.5M+34.8% | $4.8M+23.1% | $3.9M |
| Gross Profit | N/A | $619K-15.6% | $733K+65.8% | $442K+127.8% | $194K+71.7% | $113K-1.7% | $115K-12.9% | $132K+61.0% | $82K-62.4% | $218K-74.1% | $843K+45.5% | $580K+51.9% | $382K-75.1% | $1.5M+347.9% | -$618K-488.3% | $159K |
| R&D Expenses | N/A | $3.7M-3.1% | $3.8M+9.0% | $3.5M+48.5% | $2.3M+150.8% | $929K-8.1% | $1.0M-19.5% | $1.3M+816.8% | $137K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $4.4M-34.7% | $6.8M-21.0% | $8.6M-35.7% | $13.3M+68.1% | $7.9M+32.5% | $6.0M+69.6% | $3.5M+102.9% | $1.7M-23.7% | $2.3M-15.9% | $2.7M-34.7% | $4.1M+90.0% | $2.2M-28.4% | $3.0M-35.3% | $4.7M-35.4% | $7.3M |
| Operating Income | N/A | -$7.4M+24.0% | -$9.8M+15.3% | -$11.6M+25.0% | -$15.4M-76.8% | -$8.7M-27.1% | -$6.9M-47.8% | -$4.6M-159.5% | -$1.8M+12.9% | -$2.1M+29.3% | -$2.9M+33.1% | -$4.3M-71.8% | -$2.5M-1.8% | -$2.5M+66.9% | -$7.5M+52.7% | -$15.9M |
| Interest Expense | N/A | $5K0.0% | $5K0.0% | $5K0.0% | $5K+66.7% | $3K | N/A | N/A | $31K-86.2% | $223K+4.5% | $214K-25.3% | $286K-1.8% | $292K-30.5% | $419K-57.4% | $984K-29.5% | $1.4M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $2K | $0-100.0% | $14K+2392.4% | $579-88.8% | $5K | $0+100.0% | -$365K-311.3% | $173K-95.8% | $4.1M |
| Net Income | N/A | -$7.1M+45.2% | -$13.0M-13.0% | -$11.5M+23.4% | -$15.0M-70.4% | -$8.8M-20.5% | -$7.3M-78.5% | -$4.1M-129.4% | -$1.8M+4.4% | -$1.9M+33.5% | -$2.8M+39.1% | -$4.6M-52.7% | -$3.0M-34.2% | -$2.3M+70.9% | -$7.8M+61.7% | -$20.2M |
| EPS (Diluted) | — | -$0.09+59.1% | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | -$0.07 | -$0.17+45.2% | -$0.31 | -$0.37-15.6% | -$0.32 | -$2.66 | -$1.34 |
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IGC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.7M-11.7% | $9.9M-42.4% | $17.2M-36.0% | $26.8M-25.2% | $35.9M+23.7% | $29.0M-15.9% | $34.5M+217.6% | $10.9M-3.8% | $11.3M-40.2% | $18.9M-7.2% | $20.3M+14.6% | $17.7M-7.9% | $19.3M-23.8% | $25.3M+39.1% | $18.2M |
| Current Assets | $2.9M-21.8% | $3.7M-42.7% | $6.5M-57.2% | $15.1M-35.7% | $23.5M+32.4% | $17.8M-33.6% | $26.7M+733.8% | $3.2M-10.5% | $3.6M-6.8% | $3.8M-14.2% | $4.5M+19.1% | $3.8M-12.0% | $4.3M-18.2% | $5.2M-20.2% | $6.5M |
| Cash & Equivalents | $405K-66.2% | $1.2M-62.5% | $3.2M-69.4% | $10.5M-28.1% | $14.5M+100.4% | $7.3M-71.7% | $25.6M+1444.6% | $1.7M+208.2% | $538K-63.9% | $1.5M+80.8% | $824K-19.7% | $1.0M-3.6% | $1.1M+89.1% | $563K-64.4% | $1.6M |
| Inventory | $1.4M-11.7% | $1.5M-41.9% | $2.7M-25.3% | $3.5M-35.2% | $5.5M+29.0% | $4.2M+1611.7% | $248K-49.0% | $486K | $0-100.0% | $162K-77.2% | $710K+16.0% | $612K+50.3% | $407K+5.1% | $387K+190.2% | $134K |
| Accounts Receivable | $34K-12.8% | $39K-63.6% | $107K-14.4% | $125K-28.6% | $175K+31.6% | $133K+58.3% | $84K-84.9% | $558K-25.9% | $753K-21.8% | $963K-3.1% | $993K+75.4% | $566K-46.9% | $1.1M-35.0% | $1.6M-50.4% | $3.3M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $198K-83.2% | $1.2M+20.2% | $983K | $0 | $0-100.0% | $966K+135.3% | $410K |
| Total Liabilities | $2.4M-6.4% | $2.6M+13.9% | $2.3M-22.9% | $2.9M-4.0% | $3.1M+25.2% | $2.4M+174.0% | $893K-68.0% | $2.8M-29.1% | $3.9M-19.9% | $4.9M-12.0% | $5.6M+55.5% | $3.6M-16.1% | $4.3M-54.7% | $9.4M-17.8% | $11.5M |
| Current Liabilities | $2.3M-3.5% | $2.3M+23.3% | $1.9M-22.2% | $2.4M+3.1% | $2.4M+21.7% | $1.9M+121.6% | $878K-62.6% | $2.3M+81.9% | $1.3M-59.7% | $3.2M+30.7% | $2.4M+137.5% | $1.0M-43.5% | $1.8M-59.4% | $4.5M-31.6% | $6.6M |
| Long-Term Debt | $134K-2.2% | $137K-2.8% | $141K-2.1% | $144K-47.8% | $276K | $0 | N/A | N/A | $452K-43.6% | $801K+147.4% | $324K | $0 | N/A | N/A | N/A |
| Total Equity | $6.3M-13.5% | $7.3M-50.9% | $14.9M-37.6% | $23.9M-27.2% | $32.8M+23.6% | $26.5M-21.0% | $33.6M+316.3% | $8.1M+9.6% | $7.4M-45.4% | $13.5M-5.3% | $14.2M+4.5% | $13.6M-5.6% | $14.4M-2.7% | $14.8M+122.6% | $6.7M |
| Retained Earnings | -$120.7M-6.2% | -$113.7M-12.9% | -$100.7M-12.9% | -$89.2M-20.3% | -$74.1M-13.4% | -$65.4M-12.6% | -$58.1M-7.9% | -$53.8M-3.4% | -$52.0M-3.7% | -$50.1M-5.9% | -$47.3M-10.8% | -$42.7M-7.6% | -$39.7M-6.0% | -$37.4M-26.1% | -$29.7M |
IGC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.9M | -$4.8M+7.8% | -$5.2M+26.2% | -$7.0M+5.6% | -$7.5M+30.9% | -$10.8M-24.5% | -$8.7M-160.6% | -$3.3M-72.4% | -$1.9M-38.8% | -$1.4M-782.1% | -$158K+93.9% | -$2.6M-48.3% | -$1.7M-408.4% | $565K+111.2% | -$5.0M-90.6% | -$2.6M |
| Capital Expenditures | $47K | $112K-18.8% | $138K-55.5% | $310K+31.4% | $236K-83.9% | $1.5M-66.5% | $4.4M+29160.0% | $15K-89.0% | $136K-6.6% | $146K+19.2% | $122K+59.7% | $77K+801.9% | $8K-97.4% | $326K+5850.3% | $5K-98.1% | $285K |
| Free Cash Flow | -$5.9M | -$4.9M+8.1% | -$5.3M+27.5% | -$7.4M+4.4% | -$7.7M+37.3% | -$12.3M+6.1% | -$13.1M-290.6% | -$3.3M-61.8% | -$2.1M-34.5% | -$1.5M-449.1% | -$280K+89.5% | -$2.7M-52.0% | -$1.8M-833.2% | $239K+104.7% | -$5.0M-72.2% | -$2.9M |
| Investing Cash Flow | -$1.0M | -$442K-39.4% | -$317K-34.9% | -$235K+68.3% | -$742K-121.9% | $3.4M+135.5% | -$9.5M-3571.9% | -$260K+60.4% | -$657K-172.2% | -$241K-31.6% | -$183K+64.6% | -$518K-16904.7% | $3K+104.1% | -$75K-101.6% | $4.7M+10544.0% | -$45K |
| Financing Cash Flow | $6.8M | $4.5M+26.3% | $3.5M+3424.0% | $100K-97.6% | $4.1M-71.8% | $14.7M+24994.9% | -$59K-100.2% | $27.6M+642.9% | $3.7M+425.0% | $708K-30.0% | $1.0M-65.1% | $2.9M+67.0% | $1.7M+6170.3% | $28K+104.4% | -$626K-118.3% | $3.4M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IGC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.7%-5.8pp | 54.5%+6.0pp | 48.5%-0.4pp | 48.9%+36.3pp | 12.6%+9.8pp | 2.8%+0.2pp | 2.6%-1.2pp | 3.7%-33.9pp | 37.6%+24.3pp | 13.3%+5.7pp | 7.5%-9.2pp | 16.8%-2.3pp | 19.1%+33.8pp | -14.7%-18.6pp | 3.9% |
| Operating Margin | -585.8% | -728.5% | -1270.1% | -3886.2% | -971.5% | -168.6% | -90.8%-9.2pp | -81.6% | -354.0% | -45.6%+10.9pp | -56.5% | -111.2% | -30.9% | -178.9% | -390.0% |
| Net Margin | -560.4% | -966.5% | -1263.0% | -3782.4% | -981.2% | -179.6% | -80.1%+1.4pp | -81.4% | -321.7% | -44.1%+16.0pp | -60.1% | -133.0% | -28.1% | -184.6% | -496.8% |
| Return on Equity | -112.5%+65.1pp | -177.6%-100.4pp | -77.2%-14.3pp | -62.8%-36.0pp | -26.9%+0.7pp | -27.6%-15.4pp | -12.2%+10.0pp | -22.1%+3.2pp | -25.4%-4.5pp | -20.8%+11.6pp | -32.4%-10.2pp | -22.2%-6.6pp | -15.6%+36.6pp | -52.2%+251.4pp | -303.6% |
| Return on Assets | -81.4%+49.9pp | -131.3%-64.3pp | -67.0%-11.0pp | -56.0%-31.4pp | -24.6%+0.7pp | -25.2%-13.4pp | -11.9%+4.6pp | -16.5%+0.1pp | -16.6%-1.7pp | -14.9%+7.8pp | -22.7%-5.6pp | -17.0%-5.3pp | -11.7%+19.0pp | -30.7%+80.8pp | -111.5% |
| Current Ratio | 1.28-0.3x | 1.58-1.8x | 3.41-2.8x | 6.19-3.7x | 9.93+0.8x | 9.12-21.3x | 30.44+29.1x | 1.37-1.4x | 2.78+1.6x | 1.20-0.6x | 1.83-1.8x | 3.65+1.3x | 2.34+1.2x | 1.16+0.2x | 1.00 |
| Debt-to-Equity | 0.020.0x | 0.020.0x | 0.010.0x | 0.010.0x | 0.010.0x | 0.000.0x | 0.03-0.3x | 0.35+0.3x | 0.060.0x | 0.060.0x | 0.020.0x | 0.00-0.3x | 0.30-0.3x | 0.64-1.1x | 1.72 |
| FCF Margin | -386.1% | -396.8% | -807.6% | -1939.0% | -1366.4% | -320.9% | -65.4%+28.9pp | -94.3% | -264.8% | -4.4%+30.2pp | -34.6%+42.4pp | -77.0%-80.0pp | 3.0% | -119.7% | -71.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where IGC Pharma Inc Ranks
Frequently Asked Questions
What is IGC Pharma Inc's annual revenue?
IGC Pharma Inc (IGC) reported $1.3M in total revenue for fiscal year 2025. This represents a -5.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is IGC Pharma Inc's revenue growing?
IGC Pharma Inc (IGC) revenue declined by 5.5% year-over-year, from $1.3M to $1.3M in fiscal year 2025.
Is IGC Pharma Inc profitable?
No, IGC Pharma Inc (IGC) reported a net income of -$7.1M in fiscal year 2025.
What is IGC Pharma Inc's EBITDA?
IGC Pharma Inc (IGC) had EBITDA of -$6.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does IGC Pharma Inc have?
As of fiscal year 2025, IGC Pharma Inc (IGC) had $405K in cash and equivalents against $134K in long-term debt.
What is IGC Pharma Inc's gross margin?
IGC Pharma Inc (IGC) had a gross margin of 48.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is IGC Pharma Inc's return on equity (ROE)?
IGC Pharma Inc (IGC) has a return on equity of -112.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is IGC Pharma Inc's free cash flow?
IGC Pharma Inc (IGC) recorded an outflow of $4.9M in free cash flow during fiscal year 2025. This represents a 8.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is IGC Pharma Inc's operating cash flow?
IGC Pharma Inc (IGC) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are IGC Pharma Inc's total assets?
IGC Pharma Inc (IGC) had $8.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are IGC Pharma Inc's capital expenditures?
IGC Pharma Inc (IGC) invested $112K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does IGC Pharma Inc spend on research and development?
IGC Pharma Inc (IGC) invested $3.7M in research and development during fiscal year 2025.
What is IGC Pharma Inc's current ratio?
IGC Pharma Inc (IGC) had a current ratio of 1.28 as of fiscal year 2025, which is considered adequate.
What is IGC Pharma Inc's debt-to-equity ratio?
IGC Pharma Inc (IGC) had a debt-to-equity ratio of 0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is IGC Pharma Inc's return on assets (ROA)?
IGC Pharma Inc (IGC) had a return on assets of -81.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is IGC Pharma Inc's cash runway?
Based on fiscal year 2025 data, IGC Pharma Inc (IGC) had $405K in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is IGC Pharma Inc's Altman Z-Score?
IGC Pharma Inc (IGC) has an Altman Z-Score of -14.00, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is IGC Pharma Inc's Piotroski F-Score?
IGC Pharma Inc (IGC) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are IGC Pharma Inc's earnings high quality?
IGC Pharma Inc (IGC) reported a net loss of $7.1M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can IGC Pharma Inc cover its interest payments?
IGC Pharma Inc (IGC) reported an operating loss of $7.4M against $5K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is IGC Pharma Inc?
IGC Pharma Inc (IGC) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.